Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sunrest LifescienceNSE:SUNREST +3.06%42 Debt-to-EBITDA is 0.94 as of Mar. 2026, which is 76% below its 10-year median of 3.99. GuruFocus rates NSE:SUNREST with a GF Score™ of 42/100. The stock has 6 warning signs investors should review. Among 478 Healthcare Providers & Services companies, Sunrest Lifescience ranks better than 55.44% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Sunrest Lifescience's Debt-to-EBITDA or its related term are showing as below:
NSE:SUNREST'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.73 Med: 3.99 Max: 14.87
Current: 1.88
During the past 7 years, the highest Debt-to-EBITDA Ratio of Sunrest Lifescience was 14.87. The lowest was 0.73. And the median was 3.99.
NSE:SUNREST's Debt-to-EBITDA is ranked better than 55.44% of 478
companies
in the Healthcare Providers & Services industry
Industry Median: 2.195
vs NSE:SUNREST: 1.88
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Sunrest Lifescience Debt-to-EBITDA Related Terms
Sunrest Lifescience Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Sunrest Lifescience's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Pharmaceutical Retailers subindustry, Sunrest Lifescience's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sunrest Lifescience Debt-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Sunrest Lifescience's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Sunrest Lifescience's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Mar. 2026) EBITDA data.
Sunrest Lifescience (NSE:SUNREST) has a Debt-to-EBITDA of 0.94 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Sunrest Lifescience. This is 76% below median its historical median of 3.99. Over the past decade, Sunrest Lifescience's Debt-to-EBITDA has ranged from 0.73 to 14.87. According to the industry distribution chart, Sunrest Lifescience ranks #213 out of 478 companies in the Healthcare Providers & Services industry, placing it in the top 44.6%.
Is Sunrest Lifescience's Debt-to-EBITDA too high?
Sunrest Lifescience's current Debt-to-EBITDA of 0.94 is 76% below median its 10-year median of 3.99. Over the past 10 years, this metric has ranged from a low of 0.73 to a high of 14.87. The Healthcare Providers & Services industry median Debt-to-EBITDA is 2.20. Sunrest Lifescience's value of 0.94 is 57.2% below this industry median. Based on the distribution chart, Sunrest Lifescience ranks #213 out of 478 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Sunrest Lifescience has a GF Score™ of 42/100, reflecting its overall financial health beyond just this single metric.
How does Sunrest Lifescience's Debt-to-EBITDA compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Sunrest Lifescience ranks #213 out of 478 companies for Debt-to-EBITDA. This puts Sunrest Lifescience in the upper half of its industry. The industry median Debt-to-EBITDA is 2.20. Sunrest Lifescience's value of 0.94 is 57.2% below this benchmark. Historically, Sunrest Lifescience's own Debt-to-EBITDA has ranged from 0.73 to 14.87 over the past decade. While the company's 10-year median is 3.99 vs. the industry median of 2.20, Sunrest Lifescience has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Healthcare Providers & Services company?
The median Debt-to-EBITDA among Healthcare Providers & Services companies is 2.20, based on 478 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sunrest Lifescience's current Debt-to-EBITDA of 0.94 is 57.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Sunrest Lifescience. For the Healthcare Providers & Services industry, the median Debt-to-EBITDA is 2.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sunrest Lifescience's current Debt-to-EBITDA is 0.94, which is 76% below median its own 10-year median of 3.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sunrest Lifescience stock overvalued right now?
Sunrest Lifescience (NSE:SUNREST) has a current Debt-to-EBITDA of 0.94. The current Debt-to-EBITDA is 0.94, which is 76% below median its 10-year median of 3.99 and 57.2% below the Healthcare Providers & Services industry median of 2.20. Sunrest Lifescience's overall GF Score™ is 42/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Sunrest Lifescience (NSE:SUNREST), the current Debt-to-EBITDA is 0.94 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sunrest Lifescience Ltd is engaged in the trading business of pharmaceutical products, including capsules, tablets, syrups, ointments, gels, mouthwash, and toothpaste on a wholesale and retail basis. Its product portfolio covers categories such as anti-bacterial, anti-diarrheal, anti-fungal, anti-malarial, anti-diabetic, dental care, anti-inflammatory, nutraceuticals, and more. The company works with a network of suppliers and super suppliers, distributing products to chemists, hospitals, and dispensaries across multiple Indian states. Sunrest relies on both in-house manufacturing through its group company Trilend Pharmaceuticals and third-party manufacturers, emphasizing quality control and regulatory compliance.
42GF Score
Get the complete analysis for NSE:SUNREST
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:SUNREST has been successfully added to your 
